SAN FRANCISCO, May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and Athenex, Inc. (Nasdaq:ATNX) will present the findings of the I-SPY 2 TRIAL evaluation of Athenex's oral paclitaxel plus encequidar in combination with GSK's dostarlimab in the neoadjuvant setting at this year's American Society of Clinical Oncology (ASCO) conference.
Read more at prnewswire.comQuantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO
PR Newswire -
Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here